AUTHORS
Manuel Ricardo Espinoza-Gutarra, MD, Omer Jamy, MD2, Razan Mohty, MD3, Kimo Bachiashvili, MD4, Zaid Al-Kadhimi, MD5, Sravanti Rangaraju, MD6, Aditi Sharma, MD7, Ravi Bhatia, MD8, Rob S Welner, PhD9, Pankit Vachhani, MD10, David Figge, MD, PhD11, Jorge Cortes, MD12
AFFILIATIONS
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 University of Alabama at Birmingham, Birmingham, Alabama, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 University of Alabama at Birmingham, Birmingham, Alabama, United States
8 University of Alabama at Birmingham, Birmingham, Alabama, United States
9 University of Alabama at Birmingham, Birmingham, Alabama, United States
10 University of Alabama at Birmingham, Birmingham, Alabama, United States
11 University of Alabama at Birmingham, Birmingham, Alabama, United States
12 University of Alabama at Birmingham, Birmingham, Alabama, United States
ABSTRACT
Background:
Inflammatory AML (iAML) is an underrecognized phenotypical presentation of AML, defined here as newly diagnosed AML presenting with elevated Serum Ferritin (SF) ≥500 ng/mL and Elevated soluble Interleukin Receptor 2(sIL2r) ≥2400 U/mL or equivalent as per reference laboratory. These markers have been associated independently with poor prognosis and are components of the diagnostic criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Optimized HLH Inflammatory Index (OHI)
Methods:
From November 2025 until July 2026 consecutive newly diagnosed AML patients presenting to UAB O’Neal Comprehensive Cancer Center were screened for iAML, those with SF ≥500 ng/mL and sIL2r ≥x2ULN (ARUP Multiplex Luminex Assay, ULN=858 pg/mL) were considered as having iAML and had additional cytokine analysis performed (Mayo Clinic Cytokine Panel; including: TNFa, IL6, IFNb, IL10, MCP1, IL1b, IFNy, MIP1a, GM-CSF, sIL2r, IFNa, IL18, levels expressed in pg/mL). SF and cytokine analysis were repeated at time of end of induction (EOI) bone marrow assessment. Clinical and demographic characteristics, treatment regimens, laboratory results, imaging and clinical outcomes were obtained through retrospective chart review.
Results:
During the study period 150 patients presented to UAB with newly diagnosed AML, out of which 35 (23.3%) fulfilled initial SF and sIL2r criteria. Median age was 68 years (range 35-85), 60% (21) were male, 82.9% (29) were Non-Hispanic White, 20% (7) had AML-MRC, 11.4% (4) had t-AML and 17.1% (6) had sAML; risk stratification per ELN 2022 was 62.9% adverse, 20% intermediate and 14.3% favorable. Median Hb at diagnosis was 7.5 (4.6-11.8), PLT were 33K (5K-150K), blasts were 62% (20-97), median SF was 1316 ng/mL (509 – 30000 ng/mL) and sIL2r was 3106 U/mL (1716 – 25672 U/mL). Out 33 patients with available mutational data, 33% (11/33) had NPM1, 27% (9/33) had FLT3 ITD, 30% (10/33) had TP53, and 24% (8/33) had TET2 mutations. Of note 7 patients had concurrent FLT3 ITD and NPM1 mutations. 68.6% had fever at diagnosis, but only 20% had a microbiologically confirmed infection, 40% had splenomegaly, 8.6% had evidence of hemophagocytosis in bone marrow biopsy, 17% had hypofibrinogenemia, 5.7% had hypertriglyceridemia. 83% of patients fulfilled at least 4/8 HLH-2004 criteria. Regarding cytokines at diagnosis, median levels were (ULN; pg/mL): TNFa: 11.7 (<10); IL6: 24.3 (<5), MCP1:187 (<198), IL18:687 (<468); none of the others had medians above ULN. 71% of patients received definitive AML treatment, with the rest receiving palliative therapy: Out of those treated, 26% received intensive therapy and 46% receiving non-intensive therapy; 37% (13) achieved CRc, including 7 patients that achieved CR; 17% were primary refractory. Out of 18 patients with SF and cytokine assessment at EOI, when comparing CRc vs refractory patients, median SF was 1411 vs 5961, sIL2r was 1227 vs 2618, TNFa was 1.03 vs 2.65, IL6 was 5.65 vs 55.15, MCP1 was 170 vs 580 and IL18 was 697 vs 1556. Median EFS and OS for the entire cohort were 2.6 and 2.8 months respectively, with 11.4% of patients being able to receive allogeneic SCT, cause of dead was underlying AML in 85.7% of patients.
Conclusions:
iAML represents a very high-risk phenotype of AML patients across multiple mutational subtypes with very high rates of mortality despite modern therapies, which highlights the need for clinical intervention geared towards this population. Our analysis is limited by a relatively low number of patients and cross-lab validation of cytokine analysis.
DISCLOSURES
Manuel Ricardo Espinoza-Gutarra, MD: Abbvie - Consultancy (Includes expert testimony); Omer's - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony)